Investment
Features
FeesSafety
Academy
More
Pluang+

Bitcoin holders aged 6-12 months increased transfers to exchanges but sales remain low.

Technical Signals
19 Oct 2026
Tokenpost
View Source
Neutral
Bitcoin holders aged 6-12 months increased transfers to exchanges but sales remain low.

Bitcoin held for six to 12 months saw a rise in transfers to exchange wallets in the 30 days through October 15, with 9,100 BTC moved, representing 4.4% of total movement. Although this is an increase from 3.7% in the previous month, it remains far below the 40.4% share seen in June. The total BTC movement in this age group also increased from 157,700 to 205,400 BTC, indicating active transfers. However, moving BTC to exchanges does not necessarily mean sales, as transfers can be for trading or other exchange services. Market observers note that Bitcoin still needs new buyers to push prices higher, but these buyers have not yet appeared.

Bitcoin exchange deposit share rose to 4.4% after three monthly declines, providing context for recent Bitcoin transfer activity. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 20, 2026 04:42 WIB: out of 50 major cryptocurrencies priced on Pluang, 46 rose and 3 fell today. Notable movers include EOS at Rp12.649 (+8.13%), DOT at Rp20.410 (+7.63%) with a Pluang order activity of 83% Sell / 17% Buy, and ATOM at Rp31.274 (+7.33%) with a Pluang order activity of 24% Sell / 76% Buy.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
1 hour ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
1 hour ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
2 hours ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
3 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App